Figures
Sample size requirements for demonstrating statistically significant attenuation of allergeninduced increases in percentage of sputum eosinophils (power: —: 0.70; ═: 0.75; : 0.80; – – – –: 0.85; ..: 0.90; –…–…–: 0.95). For example, a drug that blocks 50% of the allergeninduced increase in eosinophil number can be demonstrated to be significant using only four subjects (90% power).
Tables
- Table 1
Eosinophil counts in duplicate sputum samples obtained from asthmatic subjects currently not on maintenance treatment
Sample 1 Sample 2 Difference Mean log10transformed data 0.674 0.672 0.002 sd log10transformed data 0.729 0.743 0.333 Geometric mean 4.722 4.698 - Table 2
The attenuating effect of various steroid formulations, doses and treatment durations on sputum eosinophils. Improvements are expressed as percentage improvement from a pretreatment baseline
First author [Ref.] Steroid Dose µg Duration weeks Improvement % Jatakanon 8 Bud 100 4 69 Bud 400 4 71 Aldridge 22 Bud 800 6 61 Taylor 23 Cicl 100 2 36 Cicl 400 2 65 Cicl 1600 2 63 Lim 24 Bud 1600 4 71 Fahy 25 BDP 336 4 6 Turner 26 BDP 336 4 75 Bacci 27 Bud 400 3 months 91 Van Rensen 28 FP 1000 4 85 Keatings 29 PRED 30 mg 2 86 Claman 30 PRED 0.5 mg·kg−1 6 days 87 Bud: budesonide
Cicl: ciclosporin
BDP: beclomethasone dipropionate
FP: fluticasone propionate
PRED: prednisone
